GlaxoSmithKline Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from GlaxoSmithKline Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 18% in 3 years; of every extra ₹100 of sales, ₹73 became extra profit. Higher than 98% of Healthcare companies in India.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹15 per ₹100 of sales comes from others' credit, against ₹7 from others' credit three years earlier. Less money tied up than 98% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 25.0 times. Higher than 97% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹109Over the last 3 years, every ₹100 of reported profit came with ₹109 of operating cash.
Higher than 51% of Healthcare companies in India.
Self-Funding Ratio
25.0×Over the last 3 years its own operating cash covered its investment spending (capex) 25.0 times.
Higher than 97% of Healthcare companies in India.
Cash Locked Ratio
−₹15Money owed to suppliers is larger than money owed by customers plus stock: ₹15 per ₹100 of sales comes from others' credit, against ₹7 from others' credit three years earlier.
Less money tied up than 98% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹73Sales grew 18% in 3 years; of every extra ₹100 of sales, ₹73 became extra profit.
Higher than 98% of Healthcare companies in India.
Asset Productivity Ratio
+18% / +30%In 3 years sales changed by +18% while total assets changed by +30%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
56.5×Debt due within a year is covered 56.5 times by its yearly operating cash.
Higher than 93% of Healthcare companies in India.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Higher than 85% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 77% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 75% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
GlaxoSmithKline Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns. Net profit rose 12% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
38.6Investors pay ₹38.6 for every ₹1 of GlaxoSmithKline Pharmaceuticals Limited's yearly profit, higher than 54% of Healthcare companies in India.
P/B ratio
18.18The share price is 18.18 times GlaxoSmithKline Pharmaceuticals Limited's book value per share, higher than 97% of Healthcare companies in India.
Market cap
₹41,228 CrThe total market value of all of GlaxoSmithKline Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 86% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹2,267 CrWhat GlaxoSmithKline Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹133.84Net worth divided by the number of shares. The share price of ₹2,434 is 18.2 times this, which is the P/B above.
Return on equity (ROE)
47.1%GlaxoSmithKline Pharmaceuticals Limited earned 47.1% on its shareholders' money over the last year, higher than 97% of Healthcare companies in India.
Owes vs Owns
0.48×GlaxoSmithKline Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns (low), higher than 79% of Healthcare companies in India.
Dividend yield
2.28%GlaxoSmithKline Pharmaceuticals Limited pays 2.28% of its share price as dividends a year, higher than 97% of dividend-paying Healthcare companies in India.
Revenue growth
+2%Revenue rose 2% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit growth
+12%Net profit rose 12% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit margin
27.2%GlaxoSmithKline Pharmaceuticals Limited keeps ₹27 of every ₹100 of revenue as net profit.
Cash quality
0.9×Cash from GlaxoSmithKline Pharmaceuticals Limited's business was 0.9× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
456.6×GlaxoSmithKline Pharmaceuticals Limited's operating profit covered its interest costs 456.6 times in the year to Mar 2026.
Cash vs debt
Net cashGlaxoSmithKline Pharmaceuticals Limited held ₹2,723 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is GlaxoSmithKline Pharmaceuticals Limited's P/E ratio?
Investors pay ₹38.6 for every ₹1 of GlaxoSmithKline Pharmaceuticals Limited's yearly profit, higher than 54% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For GlaxoSmithKline Pharmaceuticals Limited: ₹41,228 Cr ÷ ₹2,267 Cr (31 Mar 2026) = 18.2.
What is GlaxoSmithKline Pharmaceuticals Limited's return on equity?
GlaxoSmithKline Pharmaceuticals Limited earned 47.1% on its shareholders' money over the last year, higher than 97% of Healthcare companies in India.
How much does GlaxoSmithKline Pharmaceuticals Limited owe compared with what it owns?
GlaxoSmithKline Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns (low), higher than 79% of Healthcare companies in India.
Does GlaxoSmithKline Pharmaceuticals Limited pay a dividend?
Yes. GlaxoSmithKline Pharmaceuticals Limited pays 2.28% of its share price as dividends a year, higher than 97% of dividend-paying Healthcare companies in India.
Is GlaxoSmithKline Pharmaceuticals Limited's revenue growing?
Revenue rose 2% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.